Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Key Highlights Include: Strong cash position of approximately $26.6 million at the end of the second quarter of 2015 and approximately $66 million as of July 28, 2015, following the...
-
Salix Pharmaceuticals, recently acquired by Valeant Pharmaceuticals, confirmed to RedHill that it continues the development of RedHill's RHB-106 encapsulated bowel preparation Salix further...
-
TEL-AVIV, Israel, July 23, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
TEL-AVIV, Israel, July 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
TEL-AVIV, Israel, July 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 15, 2015 Registration No. 333-193503 TEL-AVIV, Israel, July 15, 2015 (GLOBE...
-
RedHill has extended the term of the exclusive option agreement for the oncology drug candidate RP101 for an additional year RP101 is a proprietary, first-in-class, orally-administered,...
-
TEL-AVIV, Israel, July 14, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
The Phase III study with RHB-104 for Crohn's disease is currently ongoing in the U.S. and additional countries, with up to 120 clinical sites planned globally (the MAP US study) A Clinical...
-
Once granted, the two new U.S. patents covering RHB-104 are expected to be valid through 2029 RHB-104 is undergoing a first Phase III study for the treatment of Crohn's disease in the U.S....